Panthera Biopartners now offers the broadest range of clinical trial therapy areas of any site management organisation in the UK.

Panthera Biopartners has again broadened the range of therapy areas it can run clinical trials in to include not only vaccines, cardiovascular, general medicine, diabetes, neurology, respiratory, dermatology and rheumatology but also specialist areas such as oncology, NASH and early dementia trials. The ability to carry out trials with specialist PIs (principal investigators) will attract …

Read more

Panthera becomes first UK clinical trial site organisation to join Parexel’s Site Alliance Vaccine Network

Parexel has confirmed that Panthera Biopartners has become the first UK public or commercial clinical trial organisation to become part of the Parexel Site Alliance Vaccine Network. Parexel’s Site Alliance Vaccine Network is a global network of high performing clinical trial sites which fosters long-term collaborative relationships with select research organizations across the globe to …

Read more

Panthera moves back into recruiting and running commercial oncology clinical trials in the UK

Since announcing that it reopened its oncology clinical trials division earlier this year, Panthera Biopartners has been selected by two of the world’s largest pharma companies to run oncology trials at sites across the UK. Panthera previously had to close its Oncology division as the sites were located inside the four Rutherford Specialist Cancer clinics, …

Read more

Clinical Trials News: September 2024

Panthera’s SMO model delivers market-leading patient recruitment for vaccine trials In the post-COVID-19 period, the UK has emerged as a world leader in vaccine trials, but data from two case studies shows that Panthera is not only outperforming global sites, but also competitor sites across the UK. In a recent COVID-19 booster healthy volunteer vaccine trial, Panthera’s …

Read more

Lord Mayor opens York’s first dedicated clinical research site

The UK’s largest Site Management Organisation (SMO), Panthera Biopartners, has opened the first dedicated clinical research site in York. The site, which has been operating since May, was officially opened by the Lord Mayor of York, Councillor Margaret Wells, at an opening ceremony on 25th July 2024. The clinic is located in the Acomb Garth …

Read more

Panthera Clinical Trials News – April 2024

Click here to read more: https://lnkd.in/erHjBc6k Includes:* Panthera remains top recruiter of patients in the UK* Panthera delivers outstanding patient recruitment for cardiovascular trials* Panthera launches new clinical research clinic in York* International Clinical Trials interview – Private vs public vaccine studies, how SMOs can secure the future of UK clinical trials* Martyn Jellett appointed as …

Read more

Panthera Biopartners appoints Martyn Jellett as Associate Director Business Development to support growing commercial team

Independent clinical trial SMO (Site Management Organisation) Panthera Biopartners has appointed Martyn Jellett as Associate Director Business Development to support its expanding commercial team as the company continues to prosper and expand. Martyn has over 25 years experience in professional sales and business development and has extensive knowledge of the pharmaceutical and medical industry. Panthera, …

Read more

International Clinical Trials (ICT): Panthera interview

International Clinical Trials (ICT): Panthera interview – Private vs public vaccine studies, how SMOs can secure the future of UK clinical trials Panthera’s Ian Smith and Chris Dodd recently spoke to ICT about the differences in private versus public clinical trials, how speed is key in preclinical processes and how the UK can improve its …

Read more

Panthera contributes to Lord O’Shaughnessy’s independent review into UK clinical trials

Lord James O’Shaughnessy, former Health Minister, has been appointed by the UK government to conduct an independent review of the country’s commercial clinical trials landscape. The review will advise on how to resolve key challenges in conducting commercial clinical trials and ensure that the UK remains a global leader in the field. Lord O’Shaughnessy’s advice is expected to be published this spring.

Panthera Biopartners raises £10 million to accelerate its dedicated clinical trial site expansion

Panthera Biopartners raises £10 million to accelerate its dedicated clinical trial site expansion across the UK and Western Europe Panthera Biosciences (Panthera) has secured £10 million of investment from BGF and Gresham House Ventures, the latter investing on behalf of the Baronsmead VCTs. This investment will allow Panthera to further grow its network of dedicated …

Read more